4 Healthcare Stock Stories To Close Out the Trading Week

Johnson & Johnson (NYSE:JNJ): Closing price $92.86

Regulators in both the United States and in the European Union have said that the anti-fungal Nizoral tablets increase the danger of deadly liver injuries and harmful drug interactions, and their use should be restricted. The FDA said in a Friday statement that it has modified the drug’s label to warn that Nizoral tablets should not be the first line of treatment for a fungal infection. Meanwhile, the European Medicines Agency announced that it recommends a suspension of marketing for oral treatments which contain ketoconazole, Nizoral’s main ingredient. The EU agency said that the chance of liver damage, including hepatitis, outweighs the drug’s benefits, while the FDA said that the medication could lead to adrenal-gland problems, together with liver injuries that might be fatal or require a transplant.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

JNJ

Gentium S.p.A. (NASDAQ:GENT): Closing price $14.61

On Friday, Gentium announced that, following its request for re-examination, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Defitelio, recommending a Marketing Authorization Application under exceptional circumstances, for the treatment of severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy. Therefore, the European Commission will review the positive opinion from the CHMP, as they possess the authority to grant marketing authorization. Typically, the EC follows the recommendations of the CHMP, and delivers its final decision within three months, which will apply to all European Union countries. Once approved, each member state will then set the individual country price and the level of reimbursement.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GENT

Forest Laboratories, Inc. (NYSE:FRX): Closing price $44.38

Forest Laboratories and Pierre Fabre Laboratories announced Friday that Fetzima (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was cleared by the FDA in the treatment of Major Depressive Disorder in adults.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

FRX

Ligand Pharmaceuticals Inc. (NASDAQ:LGND): Closing price $48.88

Ligand said that the FDA has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who can not take the oral topiramate.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LGND

Don’t Miss: Does GlaxoSmithKline Stock Support Rising Prices?